BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

MONITORING FORCE GmbH Requests Acknowledgment of Flibanserin as Orphan Drug


11/19/2009 8:43:56 AM

Bookmark and Share

MUNSTER, Germany, November 19 /PRNewswire/ -- MONITORING FORCE GmbH announced that they have filed on November 16th, 2009 Flibanserin in the indication treatment-relevant levodopa-induced dyskinesia in Parkinson's disease for orphan drug status designation with the European Medicines Agency (EMEA). Levodopa-induced dyskinesia is a complication of the mainstay treatment in advanced Parkinson's and a serious burden to some of those affected, since it may be disabling for the patients and preventing them from receiving optimal treatment for Parkinson's.

Flibanserin is a 5-HT1a agonist and a 5-HT2a antagonist and thus fits in with the current theory on levodopa-induced dysinesia that dyskinesia is caused by the release of dopamine from serotonergic neurons. MONITORING FORCE is preparing to file another orphan drug status application with the United States Food and Drug Administration (FDA) and expects the first clinical trial in Parkinson's patients to start by mid-2010.

MONITORING FORCE GmbH is a clinical research company based in Munster/Germany with affiliates in the United States, France, Italy and other countries. MONITORING FORCE does contract research for the pharmaceutical industry as well as re-purposing drug development projects on their own. MONITORING FORCE has been founded in Germany in 1995 and spread to other countries since. Parkinson's disease is a primary focus of the company.

CONTACT: General Manager, MONITORING FORCE GmbH, Bahnhofstrasse 111, 48143
Munster, Germany, Tel.: +49-251-214-01-30, +49-251-26-39-577 (DD), Fax:
+49-251-21-401-53-9, Mobile: +49-171-869-82-40, beck@monitoring-force.com;
Contact (Media): Aysun Ertan, Project Manager, Targa Communications,
Goethestrasse 22, 60313 Frankfurt am Main, Germany, Tel.:
+49-69-66-36-83-98, Fax: +49-69-66-36-83-99, ae@targacommunications.de



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES